Please ensure Javascript is enabled for purposes of website accessibility

Here's Why NextCure Stock Blew Through the Roof Tuesday

By Cory Renauer - Updated Nov 6, 2019 at 9:17AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Good news from an extremely small number of patients led to Tuesday's enormous bump.

What happened

Shares of NextCure (NXTC -1.46%), a clinical-stage biopharmaceutical company developing new cancer drugs, exploded higher this morning. Updated clinical trial results from a handful of non-small cell lung cancer patients sent the biotech stock 225.8% higher as of 3:22 p.m. EST on Tuesday.

So what

NextCure made its stock-market debut in May. At the moment, a Siglec-15 (S15) antibody called NC318 is its only new drug candidate in clinical-stage testing.

Businessperson with a jetpack

Image source: Getty Images.

In March the company told us that NC318 shrank tumors for one lung-cancer patient treated in a proof-of-concept study. The stock took off like a rocket today when investors learned that one patient achieved complete remission, another experienced tumor shrinkage, and three more haven't gotten any worse.

The experimental cancer drug's target, S15, shuts down immune-system attacks against foreign cells before neighboring healthy cells get caught in the fray. This pathway is often exploited by cancer cells, which allows tumors to grow unchecked. If this sounds familiar, it's because blockbuster cancer therapies like Keytruda work similarly, by aiming at a different target called PD-L1.

Third-quarter sales of Merck & Co.'s (MRK -2.67%) Keytruda jumped 62% year over year to an annualized $12.4 billion, even though the drug only helps some patients. Expectations for NextCure and NC318 are soaring because S15-positive tumors tend to be PD-L1-negative, and NC318 could become as popular as Keytruda if clinical trial results continue to impress.

Now what

Before you run out and buy a heap of NextCure shares, it's important to understand just how difficult it is to draw any meaningful conclusions from the results we've seen so far. The ongoing proof-of-concept trial is testing six ascending dosage strengths, from 8 milligrams to 800 milligrams, in 43 patients with tumors that originated in five different organs.

Among the first 32 evaluable patients, NextCure has reported just two responses. If we only focused on the group of seven lung cancer patients who have been evaluated, out of 10 enrolled, two responses so far would be a great result. Two responses among 32 patients, however, is nothing to write home about.

On Nov. 9, at the Society for Immunotherapy of Cancer meeting, NextCure will present results for all 43 patients who have been treated with its lead candidate. It's probably best to wait for a little more confirmation that the pair of responses observed so far wasn't just a mirage.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

NextCure, Inc. Stock Quote
NextCure, Inc.
NXTC
$4.71 (-1.46%) $0.07
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$91.89 (-2.67%) $-2.52

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.